Higher FOXP3 levels were also associated with less disease recurrence in stage II CRC (Figure 7C), and although the FOXP3 expression levels in the primary tumours were different between patients with and without disease recurrence in stage III as various time points (Figure 7D), these differences were not as marked as in stage II disease. This evidence concerns the gene FOXP3 and colorectal carcinoma.